$BRKR News

Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry

Wolfe Research Assumes Bruker at Peer Perform

Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology

At ASMS, Bruker Launches TimsMRMS System, Focused On Trapped Ion Mobility Separation To Ultra-high-resolution Magnetic Resonance Mass Spectrometry

Q1 Earnings Highs And Lows: Bruker (NASDAQ:BRKR) Vs The Rest Of The Research Tools & Consumables Stocks

Bruker: Earnings Recovery Priced In, Growth Still Missing

Is Bruker (BRKR) Quietly Redefining Its Moat With Ultra-High-Field Preclinical MRI Leadership?

Champalimaud Foundation’s Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI

Bruker Announces Commissioning Of BioSpec 18 Tesla Preclinical MRI At Champalimaud Foundation In Lisbon, Portugal

Assessing Whether Bruker (BRKR) Looks Undervalued After Recent Share Price Momentum

UBS Maintains Neutral on Bruker, Raises Price Target to $45

Citigroup Maintains Neutral on Bruker, Raises Price Target to $44

TD Cowen Maintains Hold on Bruker, Raises Price Target to $45

Bruker (BRKR) Q1 2026 Earnings Transcript

Barclays Maintains Overweight on Bruker, Raises Price Target to $53

Bruker Q1 Earnings Call Highlights

Opportunity Insights for the $1.1 Billion Preclinical Imaging Industry, 2026 - Bruker Corp., Cubresa, and Siemens Healthineers Lead

Bruker (NASDAQ:BRKR) Beats Q1 Estimates but Maintains Cautious Full-Year Guidance Amid Organic Revenue Decline

Bruker’s (NASDAQ:BRKR) Q1 CY2026: Strong Sales

Full Transcript: Bruker Q1 2026 Earnings Call